Bringing science to life

Clinical insights

Overall Response Rate and solid tumors – the magic number… to date

With the rise of immunotherapies for cancer, the limitations of RECIST-based evaluation are becoming more important.

Leadership & innovation

Adaptive clinical trials: Accelerating the future of immunotherapy

As we celebrate medical and scientific advances, we must also recognize the challenges in how we evaluate and deliver new treatments.